PMID- 35945754
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 31
DP  - 2022 Aug 5
TI  - The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal 
      squamous cell carcinoma.
PG  - e29555
LID - 10.1097/MD.0000000000029555 [doi]
LID - e29555
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the most common 
      forms of head and neck cancers. However, few studies have focused on the 
      correlation between competing endogenous RNA (ceRNAs) and immune cells in LSCC. 
      METHODS: RNAseq expression of LSCC and adjacent tissues were downloaded from The 
      Cancer Genome Atlas to establish a ceRNA network. The key gene in ceRNA was 
      screened by the cox regression analysis to establish a prognostic risk assessment 
      model. The CIBERSORT algorithm was then used to screen important 
      tumor-infiltrating cells related to LSCC. Finally, co-expression analysis was 
      applied to explore the relationship between key genes in the ceRNA network and 
      tumor-infiltrating cells. The external datasets were used to validate critical 
      biomarkers. RESULTS: We constructed a prognostic risk assessment model of key 
      genes in the ceRNA network. As it turned out, Kaplan-Meier survival analysis 
      showed significant differences in overall survival rates between high-risk and 
      low-risk groups (P < .001). The survival rate of the high-risk group was 
      drastically lower than that of the low-risk group, and the AUC of 1 year, 3 
      years, and 5 years were all above 0.7. In addition, some immune infiltrating 
      cells were also found to be related to LSCC. In the co-expression analysis, there 
      is a negative correlation between plasma cells and TUBB3 (r = -0.33, P = .0013). 
      External dataset validation also supports this result. CONCLUSION: In this study, 
      we found that some key genes (SLC35C1, CLDN23, HOXB7, STC2, TMEM158, TNFRSF4, 
      TUBB3) and immune cells (plasma cells) may correspond to the prognosis of LSCC.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Dan
AU  - Li D
AUID- ORCID: 0000-0003-4876-7879
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Dong, Kaifeng
AU  - Dong K
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Su, Jing
AU  - Su J
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Xue, Haitao
AU  - Xue H
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Tian, Junhai
AU  - Tian J
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Wu, Yongfeng
AU  - Wu Y
AD  - Department of Otolaryngology, The First Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
FAU - Wang, Jingtian
AU  - Wang J
AD  - Otorhinolaryngology Surgery, The Fourth Hospital of Hebei Medical University, 
      Hebei ProvinceChina.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HOXB7 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
RN  - 0 (TMEM158 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks
MH  - *Head and Neck Neoplasms/genetics
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - *Laryngeal Neoplasms/pathology
MH  - Membrane Proteins/genetics
MH  - Prognosis
MH  - *RNA, Long Noncoding/genetics/metabolism
MH  - RNA, Messenger/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - Tumor Suppressor Proteins/genetics
PMC - PMC9351901
COIS- The authors have no funding and conflicts of interest to declare.
EDAT- 2022/08/11 06:00
MHDA- 2022/08/12 06:00
PMCR- 2022/08/05
CRDT- 2022/08/10 01:01
PHST- 2022/08/10 01:01 [entrez]
PHST- 2022/08/11 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2022/08/05 00:00 [pmc-release]
AID - 00005792-202208050-00048 [pii]
AID - 10.1097/MD.0000000000029555 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Aug 5;101(31):e29555. doi: 
      10.1097/MD.0000000000029555.